A cardiovascular outcomes study of Lyxumia (lixisenatide) in high-risk patients with Type 2 diabetes has shown that the drug is not inferior, although not superior, to placebo, according to the study’s sponsor, Sanofi SA. The Phase 3b trial is called ELIXA.
